logo

RDY

Dr. Reddy'S Laboratories·NYSE
--
--(--)
--
--(--)
8.24 / 10
Outperform

RDY's fundamental health is rated Outperform with an 8.2/10 score. Key positives include a robust 48.59% interest-coverage ratio, 16.61% YoY revenue growth, and a 74.55% net-profit-to-total-profit ratio, all of which place the company in high-performing quartiles. Asset-MV (-0.567) and Cash-MV (0.029) show moderate balance sheet strength. These metrics collectively indicate solid operational efficiency and financial resilience, supporting a strong fundamental stance.

Fundamental(8.24)SentimentTechnical

Analysis Checks(10/10)

Revenue-MV
Value-0.12
Score3/3
Weight17.80%
1M Return11.03%
Total operating revenue (YoY growth rate %)
Value16.61
Score3/3
Weight1.15%
1M Return0.88%
Inventory turnover ratio
Value2.01
Score3/3
Weight-1.39%
1M Return-1.05%
Profit-MV
Value5.21
Score3/3
Weight17.77%
1M Return10.40%
PB-ROE
Value0.93
Score3/3
Weight20.56%
1M Return13.65%
Interest coverage ratio (EBIT / Interest expense) (%)
Value48.59
Score2/3
Weight-1.54%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value16.61
Score2/3
Weight0.13%
1M Return0.10%
Asset-MV
Value-0.57
Score3/3
Weight22.67%
1M Return11.94%
Net profit / Total profit (%)
Value74.55
Score2/3
Weight-1.22%
1M Return-0.98%
Cash-MV
Value0.03
Score3/3
Weight24.07%
1M Return12.04%
Is RDY fundamentally strong?
  • RDY scores 8.24/10 on fundamentals and holds a Discounted valuation at present. Backed by its 11.40% ROE, 16.26% net margin, 18.37 P/E ratio, 2.81 P/B ratio, and 1.47% earnings growth, these metrics solidify its Outperform investment rating.